FSD Pharma Announces the Filing of an Amended Annual MD&A for 2018

About this update from Quantum Biopharma Ltd. Subordinate Voting Shares Class B

[{"type":"text","content":"\n\n\n\nFSD Pharma Announces the Filing of an Amended Annual MD&A for 2018\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nFSD Pharma Announces the Filing of an Amended Annual MD&A for 2018\nCanada NewsWire\nTORONTO, Oct. 23, 2019\n\n\n\nTORONTO, Oct. 23, 2019 /CNW/ - FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) (\"FSD\" or the \"Company\") announces that an amended and restated management's discussion and analysis for the year ended December 31, 2018 (the \"Amended 2018 MD&A\") has been filed on SEDAR to better comply with National Instrument 51-102 – Continuous Disclosure Obligations. The Amended 2018 MD&A was prepared following a continuous disclosure review by the Ontario Securities Commission (\"OSC\") of the Company's disclosure record.\n\n \n \n\n \nThe Amended 2018 MD&A was filed to address comments received from OSC staff and in order to improve the Company's disclosure. Specifically, the Amended 2018 MD&A has been revised:\nto provide an analysis of factors that have caused period to period variances in key financial statement balances as well as a discussion of factors which have caused variances in both revenue and profit or loss over the Company's recently completed fiscal quarters; to provide a breakdown of applicable material components of certain expenses; to clarify the disclosure on the status of the construction of the Company's facility in Cobourg, Ontario, and to update the related risk factor; to provide more comprehensive disclosure regarding the Company's liquidity and capital resources to identify those persons party to Related Party Transactions disclosed in the Amended MD&A; and to remove content deemed promotional by the OSC.The revisions relate only to the management's discussion and analysis and no changes were made to the financial statements for the relevant period.\nAbout FSD Pharma\nFSD Pharma is focused on the research and development of novel cannabinoid-based treatments for several central nervous system disorders including chronic pain, fibromyalgia and irritable bowel syndrome, and on...

More updates from Quantum Biopharma Ltd. Subordinate Voting Shares Class B